Minimally invasive brain science broke the listing: the company's market value is HK $14.3 billion, and minimally invasive medical is the major shareholder

RedI network Lei Jianping 7 month 15 Reported Wednesday

Minimally invasive brain science Co., Ltd （ abbreviation ：“ Minimally invasive brain science ”, Ticker ：“02172”） Listed on the Hong Kong Stock Exchange today , Another subsidiary of Chengdu minimally invasive medical technology Co., Ltd. was listed .

The issue price of minimally invasive brain science is 24.64 The Hong Kong dollar , The net amount raised is 2.78 Million Hong Kong dollars .

The cornerstone investors of minimally invasive brain science include Harvest International And Xinhuanet , A total of 890.5 Thousands of stocks , The amount of participation is 2.19 Million Hong Kong dollars .

among ,Harvest International subscription 593.7 Thousands of stocks , Xinhuanet subscription 296.8 Thousands of stocks .

The opening price of minimally invasive brain science is 24.7 The Hong Kong dollar , But it broke soon ; Up to now , The market value of minimally invasive brain science is 143 Million Hong Kong dollars .

Xiezhiyong, President of minimally invasive brain science, said , The past decade , Minimally invasive brain science has achieved rapid development , Develop multiple innovative technologies and products , Form a certain commercial scale . The company goes public , Help to form a better brand effect , Accelerate the industrialization of minimally invasive brain science , Provide comprehensive medical solutions for patients with cerebrovascular diseases .

Annual revenue 3.82 Billion

Minimally invasive brain science is a Chinese enterprise in the field of Neurointerventional medical devices , Committed to providing innovative solutions to doctors and patients . Since the first product 2004 Since its approval in , The product portfolio is accumulated in total 30 Commercial products and candidate products .

Minimally invasive brain science has successively developed and industrialized the first cerebrovascular stent in the field of nerve intervention in China apollo Intracranial artery stenting system 、 The first intracranial covered stent willis Intracranial covered stent system and the first blood flow guiding device in China tubridge Vascular reconstruction devices, etc 8 Three kinds of self-developed medical device products .

Stroke is the main cause of death for Chinese patients , And has a high incidence rate , Occupy 2020 Of the total annual mortality rate 20% above . According to the information of burning knowledge consultation , On 2020 year , China has a 80 Million patients with hemorrhagic stroke 、50 Ten thousand transient ischemic attacks （ Common symptoms of cerebral atherosclerotic stenosis ） Patients and 1.7 Millions of patients with acute ischemic stroke .

In China , Neurointerventional surgery （ In hemorrhagic stroke 、 The field of cerebral atherosclerotic stenosis and acute ischemic stroke ） The permeability is maintained at a relatively low level ,2020 In, the penetration rates of the three fields were 9.1%、1.0% And 2.7%.

The prospectus shows , Minimally invasive brain science 2019 year 、2020 year 、2021 The annual revenue is 1.84 One hundred million yuan 、2.22 One hundred million yuan 、3.82 One hundred million yuan ; The gross profit is 1.46 One hundred million yuan 、1.65 One hundred million yuan 、2.98 One hundred million yuan .

Minimally invasive brain science 2019 year 、2020 year 、2021 The annual operating profit is 5410 ten thousand 、5586 ten thousand 、8472.9 ten thousand ; The profits of the Company attributable to equity holders are 4698 ten thousand 、4529 ten thousand 、2417 ten thousand .

It can be seen that , Minimally invasive brain science 2021 Annual revenue growth 73.3%, The profit attributable to equity holders decreased year on year 46.7%.

Minimally invasive brain science 2019 year 、2020 year 、2021 The annual adjusted profits are 4698 Ten thousand yuan 、4755 Ten thousand yuan 、9191 Ten thousand yuan ; The adjusted profit margins are 25.6%、21.4%、24%.

By 2021 year 12 month 31 Japan , The cash and cash equivalents held by minimally invasive brain science are 5.93 One hundred million yuan .

Minimally invasive medicine 55%

The executive directors of minimally invasive brain science are xiezhiyong 、 Wangyiqun ; The non-executive director is Bloomberg 、 Wang Lin 、 Wu Xia ; The independent non-executive director is Dr. Xu Yi 、 Dr. zhanghaixiao 、 Xiaozhixiong .

2021 year 11 month , Minimally invasive brain science announced that it was completed as planned 1.5 The formal signing of the US $billion financing agreement , The introduction includes CICC capital 、 Many investors including Huayi capital , Previously subscribed for minimally invasive brain science 7000 Beilin capital, which has convertible bonds of US $million, has carried out share conversion and follow-up investment in this round .

IPO front , Minimally invasive medicine 54.64%, China Minimally Invasive Investment Management Co., Ltd 10.64%,Stride and Strive holding 1.96%,HNA The shareholding is 4.95%,Nectar Neuro The shareholding is 2%;

CICC Healthcare The shareholding is 4.57%,Biolink Limited The shareholding is 7.38%,Biolink NT The shareholding is 2.95%,HNMP The shareholding is 2.49%,HNNT The shareholding is 2.58%.

Minimally invasive medical capital moves frequently

Minimally invasive medicine （00853.HK） It's also a listed company ,2021 Annual revenue 7.79 Billion dollars , Year-on-year growth 15%, among , South America 、EMEA region （ The European 、 Middle East and Africa ） And North America achieved year-on-year growth respectively 29.9%、16.8% and 6.7%.

Thanks to the contribution of new product revenue and rapid market promotion , Heart valve business 、 The revenue of nerve intervention business and arterial and peripheral vascular intervention business increased year-on-year respectively 93.2%、72.5% And 45.6%.

While the mature business segment is developing at a high speed , The minimally invasive group actively arranges non vascular intervention 、 Endocrine 、 Rehabilitation medical 、 Sports medicine 、 Assisted reproduction 、 In vitro diagnosis （IVD）、 Skin and body management 、 Emerging business areas such as facial features and disinfection and sterilization .

These two years , There are many capital actions of the companies under minimally invasive medicine .

2021 year 11 month , Minimally invasive medical split minimally invasive medical robot listed on the Hong Kong Stock Exchange , Issue price 43.2 The Hong Kong dollar , The net amount raised is 14.57 Million Hong Kong dollars .

2020 year , Micro invasive Xintong to pre investment valuation 11 Billion dollars to complete a new round of financing , Introduce several well-known strategic investors , Financing amount reaches 1.3 Billion dollars ;

2020 year , Minimally invasive orthopaedics complete 5.8 Billion yuan financing agreement was signed , Introduce several well-known strategic investors ; Minimally invasive cardiac rhythm management sign B Round financing binding agreement , Financing amount reaches 1.05 Billion dollars .

2022 year 4 month , Minimally invasive electrophysiology meeting , And submit the registration to the science and Innovation Board , Plan to raise money 10.1 Billion .

among ,3.69 Billion yuan for research and development projects of electrophysiological interventional medical devices ,3 Billion yuan for production base construction projects ,1.44 Billion yuan for marketing service system construction projects ,2 Billion yuan to supplement working capital .

Minimally invasive electrophysiology is also the first company to pass ” Standard five “ Listed unprofitable medical device enterprises .

The fifth set of listing standards of the so-called science and Innovation Board , Refers to the issuer's application for listing on the science and innovation board , The estimated market value shall not be less than RMB 40 One hundred million yuan , The main business or products shall be approved by the relevant departments of the state , There's a lot of market space , At present, we have achieved phased results . If an enterprise in the pharmaceutical industry applies for the scientific innovation board according to standard 5 , At least one core product is required to be approved for phase II clinical trial .

———————————————

Lei Di was founded by Lei Jianping, a senior media person , If reproduced, please indicate the source .